secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001437749-24-033168
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports Phase 2a biomarker data for neflamapimod in DLB; RewinD-LB topline due Dec 2024
--------------------------------------------------------------------------------

- Plasma GFAP significantly reduced by neflamapimod (p=0.015 vs placebo); reductions linked to clinical improvement.
- RewinD-LB Phase 2b trial fully enrolled; topline data expected December 2024.
- Study has >95% statistical power for primary endpoint (CDR-SB) after excluding patients with tau pathology.
- DLB affects >1.4M patients in U.S. and EU with no approved treatment, per CervoMed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924033168/0001437749-24-033168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924033168/crvo20241104_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-033168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer